Dr. D.J.A. Janssen
Congestive Heart Failure (CHF) is a major cause of morbidity and mortality worldwide. In the Netherlands, almost one-third of over the age of 55 will develop CHF. The prognosis of CHF is worse than for many of the common malignant diseases with a three year mortality of about 25% for men and women.
Recently, the ‘Needs Assessment Tool: Progressive Disease – Heart Failure (NAT: PD-HF)” has been developed in Australia with the potential to be used as part of a strategy to identify and triage the management of palliative care needs experienced by people with CHF The aim of the present pilot study is to study the feasibility, acceptability and impact of the use of the NAT: PD-HF among outpatients with advanced heart failure.
More specific, objectives are:
1.1 To study clinician acceptibility of the use of the NAT: PD-HF;
1.2 To study the recruitment rate of patients and their carers;
1.3 To study completeness of clinician completion of the NAT: PD-HF, and consultation time when using the tool;
2.1 To gain preliminary data regarding the effect of the NAT: PD-HF on palliative care referral, patient–reported symptom burden, disease-specific health status, family caregiving, care dependency, and advance care planning among patients with CHF in order to inform study outcome measures and sample size calculation for a phase 3 cluster RCT.